Project Details
Description
VX14-661-108: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for th
| Status | Finished |
|---|---|
| Effective start/end date | 3/20/15 → 1/1/18 |
Funding
- VERTEX PHARMACEUTICALS INCORPORATED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.